Sex differences in treatment response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitor: a cohort study from the DANBIO registry
Despite similar baseline disease activity, females had a lower chance than males of achieving good response 4 and 12 months after starting treatment with first TNFi. The sex difference in DAS28-CRP improvement is caused by a greater decrease in CRP and SJC among males. Further, females had an increased risk of discontinuation, especially among patients aged < 50 years.
Authors
- Kirsten Duch (ORCID: https://orcid.org/0000-0002-5984-5134)
- Salome Kristensen (ORCID: https://orcid.org/0000-0001-5812-5234)
- Karen B. Lauridsen (ORCID: https://orcid.org/0000-0003-2187-8288)
- Merete Lund Hetland (ORCID: https://orcid.org/0000-0003-4229-6818)
- Lene Dreyer (ORCID: https://orcid.org/0000-0002-5156-2922)
- René Cordtz (ORCID: https://orcid.org/0000-0002-5271-2574)
- Anni Mortensen (ORCID: https://orcid.org/0009-0007-4782-9667)
Institutions
- University of Copenhagen (DK)
- Aalborg University Hospital (DK)
- Aalborg University (DK)
Publication Details
- Journal
- Scandinavian Journal of Rheumatology
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1080/03009742.2025.2471713
- Citations
- 6
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 10.01
Funders
- Gigtforeningen